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Abstract
This report defines criteria and reviews the epidemiology, pathophysiology, and management of 
the following common anorectal disorders: fecal incontinence (FI), functional anorectal pain, and 
functional defecation disorders. FI is defined as the recurrent uncontrolled passage of fecal 
material for at least 3 months. The clinical features of FI are useful for guiding diagnostic testing 
and therapy. Anorectal manometry and imaging are useful for evaluating anal and pelvic floor 
structure and function. Education, antidiarrheals, and biofeedback therapy are the mainstay of 
management; surgery may be useful in refractory cases. Functional anorectal pain syndromes are 
defined by clinical features and categorized into 3 subtypes. In proctalgia fugax, the pain is 
typically fleeting and lasts for seconds to minutes. In levator ani syndrome and unspecified 
anorectal pain, the pain lasts more than 30 minutes, but in levator ani syndrome there is 
puborectalis tenderness. Functional defecation disorders are defined by ≥2 symptoms of chronic 
constipation or irritable bowel syndrome with constipation, and with ≥2 features of impaired 
evacuation, that is, abnormal evacuation pattern on manometry, abnormal balloon expulsion test, 
or impaired rectal evacuation by imaging. It includes 2 subtypes: dyssynergic defecation and 
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inadequate defecatory propulsion. Pelvic floor biofeedback therapy is effective for treating levator 
ani syndrome and defecatory disorders.
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Anorectal disorders are defined by specific symptoms and, in the case of functional 
disorders of defecation, also with abnormal diagnostic tests. Our understanding of these 
disorders continues to evolve with the availability of newer techniques to characterize 
anorectal structure and function.1–3 Consequently, the distinction between “organic” and 
“functional” anorectal disorders may be difficult in individual patient. 1–3
Anorectal disorders, such as fecal incontinence, are usually defined by specific symptoms, 
but functional disorders of defecation require symptoms and anorectal physiological 
testing.4 While bowel symptoms recorded by questionnaires and bowel diaries are 
correlated,5 some patients may not accurately recall bowel symptoms6; hence, symptom 
diaries may be more reliable.
In this report, we examine the prevalence and pathophysiology of anorectal disorders, listed 
in Table 1, and provide recommendations for diagnostic evaluation and management. These 
supplement practice guidelines recommended by the American Gastroenterological 
Association7 and American College of Gastroenterology.8 We will not address anorectal 
symptoms secondary to a neurologic or systemic disorder. The revised diagnostic criteria 
include a minimum duration of symptoms that were selected arbitrarily to avoid the 
inclusion of self-limited conditions.
F1. Fecal Incontinence
Definition
Fecal incontinence (FI) is defined as the recurrent uncontrolled passage of fecal material for 
at least 3 months. We recognize that fecal staining of underwear may reflect poor hygiene, 
prolapsing hemorrhoids, or rectal prolapse rather than true FI, but for practical purposes it is 
included in the definition of FI. Clear mucus secretion must be excluded by careful 
questioning. Flatus incontinence is often included in the definition of anal incontinence but 
not in the current diagnosis of FI because it is difficult to define when isolated passage of 
flatus is abnormal. FI is often multifactorial and occurs in conditions that cause diarrhea, 
impair colorectal storage capacity, and/or weaken the pelvic floor (Table 2). FI is considered 
abnormal after toilet training has been achieved, generally around 4 years of age.9
Epidemiology
Prevalence—Several large community-based studies10–17 have suggested that FI is 
common, with a prevalence ranging from 7% to 15% in community-dwelling women, 18% 
to 33% in hospitals, and 50% to 70% in nursing homes.18,19 The prevalence is either 
comparable16,20 or lower in men than women.21,22 Some11,13,17,23 but not all16,24 studies 
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reported a lower prevalence in African-American than white women, but similar prevalence 
across races in men.24 Interestingly, the majority of patients seen in clinical practice are 
women.
Variations in the prevalence of FI among studies may reflect differences in survey methods, 
screening questions, reference time frame10,16,25 (1 year or past month), and definition of 
incontinence. Two studies evaluated the incidence of FI.23,26 In a community study (65 years 
and older), the incidence of FI at 4 years was 17%, with 6% having FI at least monthly.23 In 
a follow-up community study (50 years and older), the incidence of FI was 7.0%.26
Impact on quality of life and psychosocial factors—Persons with FI report that poor 
bowel control restricts their social life; other issues pertain to toilet location, hygiene/odor 
issues, coping strategies, fear, physical activities, embarrassment, and unpredictability of 
bowel habits.27 Co-existent psychological problems may include anxiety and 
depression, 28,29 poor self-esteem, and problems with sexual relationships.30 Quality of life 
issues can be evaluated by generic or disease-specific instruments, such as the Rockwood 
Fecal Incontinence Quality of Life Scale, modified Manchester Health Questionnaire, Fecal 
Incontinence and Constipation Assessment Quality of Life scale. FI symptoms can also be 
assessed by Pelvic Organ Prolapse/Incontinence Sexual Questionnaire–IUGA (International 
Urogynecology Association).31–34 There is a significant correlation between symptom 
severity and QOL in FI.31,35 FI was associated with increased mortality in some, but not all 
studies.36–38 but whether it is due to FI per se or conditions associated with FI (age and 
comorbidity) is unknown.16
Etiology and risk factors for fecal incontinence—The etiology of incontinence is 
often multifactorial. Therefore, it is more appropriate to focus on associated conditions, 
especially when they precede the onset of FI, and on risk factors for FI. In community 
surveys, bowel disturbances, especially diarrhea and rectal urgency, and the burden of 
chronic illness were more important and independent risk factors for FI than obstetric-
related pelvic floor injury (eg, forceps use, complicated episiotomy). 2,16,26,39–41 In a 
community-based cohort of 176 randomly selected women with FI and 176 without FI, the 
independent risk factors for FI were diarrhea (odds ratio [OR] = 53; 95% confidence interval 
[CI]: 6.1–471), cholecystectomy (OR = 4.2l 95% CI: 1.2–15), current smokers (OR = 4.7; 
95% CI: 1.4–15), rectocele (OR = 4.9; 95% CI: 1.3–19), stress urinary incontinence (OR = 
3.1; 95% CI: 1.4–6.5), and body mass index (per unit, OR = 1.1; 95% CI: 1.004–1.1).41 
Smoking, external sphincter atrophy, and obesity are also risk factors for FI.2,11,13,17,41 
Other conditions associated with FI include advanced age, disease burden (comorbidity 
count, diabetes), anal sphincter trauma (obstetrical injury, prior surgery), and decreased 
physical activity.11,16,17,42,43 Several diseases that affect anorectal sensorimotor 
dysfunctions and/or alter bowel habits are also associated with FI in clinical practice (Table 
2). Some of these conditions do not emerge as risk factors in community studies, possibly 
because their prevalence is relatively low. Consistent with the findings of community-based 
studies, the vast majority of women with FI who consult a physician might not have a 
neurologic or inflammatory disorder, but rather have bowel disturbances, typically diarrhea, 
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often associated with a history of obstetric risk factors. However, neurologic deficit can only 
be identified with neurophysiological tests, and these are not widely available.
The incidence of FI after vaginal delivery was 8% in a recent series.44 This may reflect 
improvements in obstetrical practices, including decreased use of instrumented vaginal 
delivery (eg, forceps), less frequent and more selective use of episiotomy, and increased use 
of cesarean sections, although a Cochrane review showed no demonstrable difference 
between cesarean sections and vaginal deliveries.45 Third-degree (ie, involving the external 
anal sphincter) and fourth-degree lacerations (ie, extending through the external and internal 
anal sphincters) are strong risk factors for anal and fecal incontinence.46 A prospective 
National Institutes of Health trial identified a nearly 2-fold increased OR of FI for women 
with sphincter injury during childbirth compared with a control group.47 The risk is highest 
for instrument-assisted deliveries, with increased odds of 1.5 for anal incontinence and a 
higher risk with forceps than vacuum extraction.48 Among women in the community, the 
median age of onset of FI is in the 7th decade, that is, many decades after vaginal delivery11 
and, therefore, how obstetric injury predisposes to FI is unclear.
Anorectal surgery for fistula, fissures, or hemorrhoidectomy and anorectal carcinoma can 
damage the sphincters.49 Impaired rectal compliance, as can occur with proctitis or after 
creation of a pouch, and fecal impaction with overflow diarrhea, can all cause FI.50–52
F1. Diagnostic Criteria a for Fecal Incontinence
1. Recurrent uncontrolled passage of fecal material in an individual with a 
developmental age of at least 4 years
aCriteria fulfilled for the last 3 months. For research studies, consider onset of symptoms 
for at least 6 months previously with 2–4 episodes of FI over 4 weeks.
Justification for Changes in Diagnostic Criteria
The earlier definition of functional fecal incontinence was cumbersome, did not facilitate 
management, and was seldom used in clinical practice or research studies. Therefore, we 
recommend the generic term fecal incontinence.
We recognize that newer sensitive diagnostic tools (eg, anal ultrasonography, pelvic 
magnetic resonance imaging [MRI], and high resolution/3-dimenstional high-definition 
anorectal pressure topography) often reveal disturbances of anorectal structure and/or 
function in a majority of patients with FI, but their relationship to symptoms is unclear, 
especially as some have more dysfunction(s) than others. Therefore, it can be challenging to 
attribute symptoms with confidence to an organic or functional cause and more studies are 
needed.
Pathophysiology
Physiological factors—Continence is maintained by several mechanisms, including 
anatomical factors (endovascular cushions, integrity of anal sphincter, and puborectalis 
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muscle), rectoanal sensation, rectal compliance, neuronal innervation, stool consistency, 
mobility, and psychological factors (Figure 1).53
Anorectal and pelvic floor musculature: Anal sphincter weakness is the most frequently 
identified abnormality in FI. Among older women, approximately 40% had reduced anal 
resting pressure and 80% reduced squeeze pressure.54 Internal anal sphincter dysfunction is 
characterized by exaggerated spontaneous relaxation of the internal anal sphincter (sampling 
reflex)55 or decreased resting pressure.54,55 The latter is associated with structural 
disturbances, that is, defects (after obstetric injury) and/or thinning (scleroderma, advanced 
age). This is best visualized by ultrasonography. Among postpartum women, the severity of 
FI was greater in women with internal anal sphincter defects.56
External anal sphincter weakness can result from one or more of the following factors: 
sphincter damage, neuropathy, myopathy, or reduced corticospinal input. In addition to the 
anal sphincters, the levator ani muscles also contribute to the pelvic barrier.57 One study 
suggested that the reduced inward traction exerted by the puborectalis in patients with FI 
correlated more closely with symptoms than did squeeze pressures, and improved after 
biofeedback therapy.58 Whereas the anal sphincters and endovascular cushions seal the anal 
canal, the levator ani and puborectalis maintain continence of solid stool by a flap-valve 
action.59–62 Patients with excessive perineal descent have a more obtuse anorectal angle, 
suggesting that the flap valve that normally maintains continence when intra-abdominal 
pressure increases is impaired.57
FI in men who generally have fecal soiling or leakage rather than gross incontinence may be 
associated with normal sphincteric function63–67; iatrogenic anal injury (eg, after perianal 
procedures); or dyssynergic defecation,68 wherein high anal resting pressure entraps feces 
during defecation and subsequently expels them69 ; radiation therapy70; or isolated 
weakness of the internal anal sphincter.
Rectal compliance and rectoanal sensation: Stool is often transferred into the rectum by 
colonic high-amplitude propagated contractions, which tend to occur after awakening or 
meals.71 Rectal distention by stool is associated with several processes that serve to preserve 
continence or, if appropriate, proceed to defecation. Rectal distention induces reflex 
relaxation of the internal anal sphincter and is perceived as a sensation of rectal fullness, as 
if the rectum were uncomfortably full of flatus or feces. If defecation is inconvenient, the 
desire to defecate prompts voluntary contraction of the external sphincter and puborectalis 
muscle72 ; this sensation wanes, together with the sense of urgency, as the rectum 
accommodates to hold more stool.
The sphincter pressures alone do not always distinguish continent from incontinent subjects. 
Reduced rectal sensation allows stool to enter the anal canal and perhaps leak before the 
external sphincter contracts.55,72,73 Decreased rectal sensitivity (rectal hyposensitivity) and 
increased rectal compliance can also contribute to fecal retention by decreasing the 
frequency and intensity of the urge (and hence the motivation) to defecate. Conversely, fecal 
retention may reduce rectal sensation, perhaps by altering rectal tone and viscoelastic 
properties, or by affecting afferent nerve pathways.74
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Rectal hypersensitivity, perhaps a marker of concomitant irritable bowel syndrome 
(IBS),55,75 may be associated with reduced rectal compliance and repetitive rectal 
contractions during rectal distention. 54,76 Rectal capacity is also reduced in women with FI 
and associated with the symptom of urgency54,77 In addition, rectal hypersensitivity cannot 
be entirely explained by disturbances in rectal compliance. Anal sphincter relaxation may 
occur during, or independent of, rectal distention, or along with colonic high-amplitude 
propagated contractions, which enables the anal lining to periodically “sample” rectal 
contents and ascertain whether rectal contents are gas, liquid, or stool. 74,78 Sampling 
occurred less frequently in incontinent patients, perhaps depriving them of sensory 
information.74 In addition to anorectal dysfunctions, continence can also be affected by 
disturbances of stool consistency and/or delivery, impaired mental faculties, and mobility. 
These observations confirm that FI is a heterogeneous disorder and that patients often 
exhibit more than one deficit (Table 2).
Clinical Evaluation
History—It is essential to develop a rapport with FI patients and, with tact and skill, 
evaluate its severity, awareness for stooling, and conditions that predispose, including the 
type (solid, liquid, and/or gas), quantity, and frequency. Staining, soiling, and seepage reflect 
the nature and severity of FI.20 Soiling indicates leakage that is more extensive than staining 
of underwear and can be specified further (ie, soiling of underwear or furnishing/bedding). 
Seepage refers to leakage of small amounts of stool.
Characterization of bowel habit is important and the Bristol Stool Form Scale and bowel 
diaries can be useful.79 Constipation with fecal impaction is a significant risk in nursing 
homes.36,80 Factors that cause or exacerbate incontinence via loose stools (eg, laxatives, 
artificial sweeteners) and anorectal surgical procedures (eg, lateral sphincterotomy) or other 
mechanisms (eg, smoking, obesity) should be considered. Conversely, agents that cause 
constipation may predispose to fecal retention and overflow. Recognizing the timing of 
incontinence (eg, whether predominantly during or after events such as meals, bowel 
movements, exercise, or at night) can provide clues to etiology and management.40 History 
taking should also include consideration of conditions that are a secondary cause of FI, such 
as multiple sclerosis, diabetic neuropathy, or scleroderma.
Urge vs passive FI can provide clues to the pathophysiology. Incontinence for solid stool 
suggests more severe sphincter weakness than liquid stool alone.81 Patients with urge 
incontinence have a sensation of the desire to defecate before leakage, but cannot reach the 
toilet on time. Conversely, patients with passive incontinence have diminished or no 
awareness of the desire to defecate before the incontinent episode. Patients with urge 
incontinence often have reduced squeeze pressures82 and/or squeeze duration,83 reduced 
rectal capacity, and increased perception of rectal balloon distention,54,84 whereas patients 
with passive incontinence often have lower resting pressures.82,83
Several FI instruments–Wexner (Cleveland Clinic), Vaizey (St Marks), Rockwood, Fecal 
Incontinence and Constipation Assessment, and the bowel version of the International 
Consultation of Incontinence questionnaire–are currently used in clinical studies to rate the 
severity of FI 10,31,35,85–87 and are validated instruments. Currently, success in therapeutic 
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trials is typically defined as a 50% reduction in the number of episodes of FI or days per 
week,88 although a patient’s perspective may differ and more meaningful outcome measures 
are required. 80,90
Physical examination including digital rectal evaluation—A multisystem and 
abdominal examination and focused neurologic examination is often necessary in FI patients 
with neurologic symptoms.
A digital rectal examination (DRE) should be conducted in the left lateral position and 
before enemas or laxatives are given. Inspection may reveal scars from previous surgery or 
obstetric injury or a patulous sphincter or perianal fecal soiling or dermatitis. An absent 
anocutaneous reflex in response to gentle stroking of the perianal region suggests nerve 
impairment. After inspection, anorectal digital palpation should be conducted. This may 
reveal external anal sphincter and/or puborectalis weakness or defects,91 stool impaction, 
and presence of dyssynergia during simulated defecation. A meticulous DRE performed by 
an experienced examiner had a positive predictive value of 67% and 81% for identifying low 
resting and squeeze pressures, respectively.92
Diagnostic testing—Testing should be tailored to the patient’s clinical problem, severity, 
possible etiology, impact on quality of life, and response to medical management.
Endoscopy: Endoscopic assessment of the rectosigmoid mucosa or full colonoscopy with 
biopsies may be considered in patients with diarrhea or recent change in bowel habit.
Manometry evaluation: Anorectal manometry (ARM) assesses continence and defecatory 
mechanisms by determining:
1. resting anal pressure, which is predominantly (ie, approximately 70%) 
attributable to internal anal sphincter function;
2. squeeze pressure: the strength and duration of voluntary external anal 
sphincter contraction and puborectalis contraction;
3. presence of an internal anal sphincter inhibitory reflex;
4. threshold volume of rectal distention required to elicit the first sensation of 
distention, a sustained feeling of urgency to defecate, and the maximum 
tolerable volume;
5. whether attempted defecation is accompanied by increased intra-
abdominal pressure and relaxation of the pelvic floor muscles (normal), or 
by paradoxical contraction of the pelvic floor muscles, which may be 
relevant to symptoms; and
6. rectal compliance can be evaluated by assessing the pressure–volume 
relationship during stepwise distention of a latex balloon, but it is 
preferable to do so with an infinitely compliant polyethylene balloon and a 
barostat.
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The methods used for ARM, including solid-state probe, high-resolution ARM, and 3-
dimensional high-definition ARM systems, and its measurements and interpretation are 
detailed elsewhere.93–95
Anal endosonography: Anal endosonography identifies anal sphincter thinning and/or 
defects that are often clinically unrecognized and may be amenable to surgical repair. 96,97 
Endosonography reliably identifies anatomic defects or thinning of the internal sphincter, 
whereas interpretation of external sphincter images may pose technical challenges. In 
contrast, 3-dimensional endosonography can measure the length and volume of the external 
anal sphincter and atrophy.98 Endoanal MRI, 99,100 and vaginal ultrasound can provide 
additional information.101
Defecography: Defecography is useful only for selected patients with FI, particularly before 
surgery, to identify or confirm structural alterations of the pelvic floor.
Pelvic magnetic resonance imaging: MRI is the only imaging modality that can visualize 
both anal sphincter anatomy and global pelvic floor motion (ie, anterior, middle, and 
posterior compartments) in real time without radiation exposure.102 Endosonography is the 
first choice for anal sphincter imaging in FI because it is widely available and the internal 
sphincter is visualized more clearly. MRI is more useful for identifying external sphincter 
atrophy and a patulous anal canal, which is a marker of not only anal sphincter injury, but 
disturbances beyond sphincter injury, such as damage to the anal cushions or anal 
denervation.54,103
Neurophysiologic tests: Neurophysiological tests can characterize disturbances in the motor 
and sensory innervation of the anorectum and pelvic floor muscles. These tests include 
pudendal nerve terminal motor latencies, electromyography (EMG), rectoanal sensory tests, 
and motor evoked potentials. There are several methodological limitations to pudendal nerve 
terminal motor latencies, and the utility of this measurement has been questioned.7 Needle 
EMG can identify normal, neurogenic, or muscle injury. 57,104 Recently, prolonged rectal 
and anal motor evoked potentials have been shown in a majority of FI patients, suggesting 
that neurophysiologic dysfunction plays an important role.105
Treatment
Management of FI must be tailored toward correction of clinical manifestations.
Bowel habit modification with dietary or pharmacological interventions—Loose 
stools are a major risk factor for FI.2,40 Correction of reversible factors like laxatives or 
other medications can help. Dietary trials (eg, low lactose or low fructose) in selected 
patients can normalize stool form. Among fiber supplements, only psyllium but not gum 
arabic or carboxymethylcellulose, improved FI compared with placebo.106 Loperamide 
given at an adequate dose (ie, 2–4 mg, 30 minutes before meals) can improve stool 
consistency and increase internal sphincter tone, thereby reducing incontinence.107 
Diphenoxylate, combined with atropine, is an alternative to loperamide, but there may be 
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anticholinergic side effects.108 In an open-label study of 18 patients, amitriptyline (20 mg 
daily), which has anticholinergic effects, improved FI in most patients.109
Patients with constipation, fecal impaction, and overflow incontinence often benefit from a 
program to increase emptying of the colorectum by various means. For example, a regimen 
consisting of a daily osmotic laxative (lactulose 10 mL twice daily) plus a weekly enema 
was useful in the majority of elderly patients with FI, including those with dementia.110 
However, loosening the stool may aggravate FI. Other measures aimed at improving rectal 
emptying, such as the use of suppositories or enemas, fiber supplementation, oral laxatives, 
and correction of any abnormal toileting behavior, or positioning and biofeedback may be 
helpful.111
Rectal cleansing and anal plug devices—In patients who fail bowel modification and 
biofeedback therapy, periodic rectal cleansing is a practical solution. It should be considered 
particularly in patients with neurogenic bowel dysfunction.112–115 Plug devices may also be 
useful in some patients with seepage.115
Biofeedback therapy—Biofeedback is based on the principle of operant conditioning or 
instrumental learning.116 One randomized controlled trial showed that biofeedback therapy 
is superior to Kegel exercises.117
Surgical approaches—Anal sphincter repair, although well established, does not appear 
to be effective in the long-term.118 Sacral nerve stimulation and anal submucosal injection of 
dextranomer in stabilized hyaluronic acid [NASHA Dx]), a bulking agent, are both approved 
by the US Food and Drug Administration for the treatment of FI. In the pivotal US 
multicenter study of sacral nerve stimulation, at 5-year follow-up, 76 of 120 (63%) patients 
were available, of whom, 36% reported complete continence and 89% were deemed a 
therapeutic success.119 However, this and nearly all other studies with sacral nerve 
stimulation have been uncontrolled. In a crossover study of 34 patients, the number of 
episodes of FI declined by 90% during stimulation vs 76% without stimulation.120
In the pivotal trial of NASHA Dx (206 patients), the proportion of patients achieving a 50% 
FI episode reduction was higher for NASHA Dx (52%) than sham injections (31%), this 
response was sustained up to 3 years in some patients.121,122
F2. Functional Anorectal Pain
Three types of functional anorectal pain disorders have been described: proctalgia fugax, 
levator ani syndrome, and unspecified. They are primarily distinguished on the basis of the 
duration of pain and the presence or absence of anorectal tenderness. Despite some 
differences, there is significant overlap among these conditions.123
F2a. Levator Ani Syndrome
Definition—In levator ani syndrome, the pain is often described as a vague, dull ache or 
pressure sensation high in the rectum that is often worse with sitting than with standing or 
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lying down. Physical examination may reveal spasm of levator ani muscles and tenderness 
on palpation, more often on the left than right side, or of the pelvic floor or vagina.124
Epidemiology—In one survey, the prevalence of anorectal pain due to all causes and 
symptoms of levator ani syndrome elicited by questionnaire were 11.6% and 6.6%, 
respectively.125
F2a. Diagnostic criteriaa for Levator Ani Syndrome
Must include all of the following:
1. Chronic or recurrent rectal pain or aching
2. Episodes last 30 minutes or longer
3. Tenderness during traction on the puborectalis
4. Exclusion of other causes of rectal pain, such as inflammatory bowel 
disease, intramuscular abscess and fissure, thrombosed hemorrhoids, 
prostatitis, coccygodynia, and major structural alterations of the pelvic 
floor.
aCriteria fulfilled for the last 3 months with symptom onset at least 6 months before 
diagnosis.
F2b. Diagnostic Criteria for Unspecified Functional Anorectal Pain
Symptom criteria for chronic levator ani syndrome but no tenderness during posterior 
traction on the puborectalis muscle
Justification for Changes in Diagnostic Criteria
The previous classification included chronic proctalgia that was subcategorized into levator 
ani syndrome, unspecified anorectal pain, and proctalgia fugax. Because chronic proctalgia 
includes many other conditions, it has been deleted, but the 3 subentities are retained. There 
are very limited published data on the duration of pain, but we believed the revised duration 
may facilitate better distinction between these entities. Reflecting the limited spatial 
discrimination of visceral pain in humans, the location of pain in proctalgia fugax has been 
revised to “rectum” instead of “anal canal or lower rectum.”
Pathophysiology
Physiological factors: Levator ani syndrome is hypothesized to result from spasm of pelvic 
floor muscles and elevated anal resting pressures.123 However, a recent randomized 
controlled study found features of dyssynergic defecation and a majority (85%) had levator 
muscle tenderness. The dyssynergia reversed after successful biofeedback, suggesting that 
rectoanal incoordination may be a pathophysiological explanation for levator 
anisyndrome.126
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Clinical evaluation—Diagnosis is based primarily on the presence of characteristic 
symptoms and physical examination findings (see definition). Evaluation often includes 
sigmoidoscopy, ultrasonography, and pelvic imaging to exclude alternative diseases.
Treatment—Treatments include electrogalvanic stimulation; biofeedback training; muscle 
relaxants, such as methocarbamol, diazepam, and cyclobenzaprine; digital massage of the 
levator ani muscles; and sitz baths. However, only 2 randomized controlled trials have been 
reported. In one, 157 patients with chronic proctalgia received either electrical stimulation or 
digital massage of the levator ani and warm sitz baths or pelvic floor biofeedback plus 
psychological counseling.126 Among patients who reported tenderness on palpation, the 
intent-to-treat analysis showed that 87% reported adequate relief of rectal pain after 
biofeedback, compared with 45% for electrical stimulation and 22% for massage. This 
improvement was maintained 12 months later. In another randomized controlled trial, 12 
patients were randomized to anal sphincter injections of either botulinum A toxin or placebo 
administered at an interval of 3 months; botulinum toxin injections were similar to placebo 
injections.127
F2c. Proctalgia Fugax
Definition—Proctalgia fugax is defined as sudden, severe pain in the rectal area, lasting for 
a few seconds to several minutes (rarely up to 30 minutes), and then disappearing 
completely.128,129 Pain is localized to the rectum in 90% of cases.130 Attacks are infrequent, 
typically occurring fewer than 5 times per year in 51% of patients.130 The pain has been 
described as cramping, gnawing, aching, or stabbing and may range from uncomfortable to 
unbearable.129 Almost 50% of patients had to interrupt their normal activities during an 
attack.131 The symptoms may awaken the patient from sleep.
Epidemiology—The prevalence of proctalgia fugax has ranged from 8% to 18% with no 
difference between the sexes.125,128 Symptoms rarely begin before puberty, but there have 
been cases reported in 7-year old children.128,129
F2c. Diagnostic Criteriaa for Proctalgia Fugax
Must include all of the following:
1. Recurrent episodes of pain localized to the rectum and unrelated to 
defecation
2. Episodes last from seconds to minutes, with a maximum duration of 30 
minutes
3. There is no anorectal pain between episodes.
4. Exclusion of other causes of rectal pain, such as inflammatory bowel 
disease, intramuscular abscess and fissure, thrombosed hemorrhoids, 
prostatitis, coccygodynia, and major structural alterations of the pelvic 
floor.
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aFor research purposes, criteria must be fulfilled for 3 months with symptom onset at 
least 6 months before diagnosis.
Pathophysiology
Physiological factors: The short duration and sporadic, infrequent nature of this disorder 
have made the identification of physiological mechanisms difficult, but abnormal smooth 
muscle contractions may be responsible for the pain.132–134 Two studies cited families in 
which a hereditary form of proctalgia fugax was found to be associated with hypertrophy of 
the internal anal sphincter and comorbid constipation.135,136 Attacks of proctalgia fugax are 
often precipitated by stressful life events or anxiety.137 In an uncontrolled unblinded study, a 
majority of patients were perfectionistic, anxious, and/or hypochondriacal.138
Clinical evaluation—Diagnosis is based on the presence of characteristic symptoms as 
described and exclusion of anorectal and pelvic pathophysiology.
Treatment—For most patients, the episodes are so brief that remedial treatment is 
impractical and prevention is not feasible, and because it is harmless, treatment will 
normally consist of reassurance and explanation. However, patients with frequent symptoms 
will require treatment. A randomized controlled trial showed that inhalation of salbutamol 
was more effective than placebo for shortening the duration of episodes of proctalgia for 
patients in whom episodes lasted 20 minutes or longer.139
F3. Functional Defecation Disorders
Definition
Chronic constipation is commonly classified as either slow colonic transit or outlet 
dysfunction, although some patients may have neither and others fulfill criteria for both. A 
large subset of outlet dysfunction has a functional defecation disorder (FDD), which is 
characterized by paradoxical contraction or inadequate relaxation of the pelvic floor muscles 
during attempted defecation and/or inadequate propulsive forces during attempted 
defecation. These disorders are frequently associated with symptoms such as excessive 
straining, feeling of incomplete evacuation, and digital facilitation of bowel movements.140 
However, symptoms (eg, digital disimpaction, anal pain) do not consistently distinguish 
patients with FDDs from those without.141–143 Thus, the criteria for FDDs must rely on both 
symptoms and physiological testing.
Several investigators have described the association of paradoxical anal contraction with 
constipation and have described dyssynergia patterns.144,145 Likewise, studies have shown 
inadequate propulsive forces as identified by decreased or absent intrarectal pressure during 
attempted defecation.141,142,145–148 These patients are clinically indistinguishable from 
patients with dyssynergic defecation. Recently, a large controlled study showed that 
dyssynergic defecation, inadequate propulsive forces, and a hybrid of both disturbances were 
uncorrelated, suggesting that the pathophysiology of dyssynergic defecation and inadequate 
propulsive forces are distinct.142 Also, these patterns are observed in asymptomatic 
controls,94,141,149,150 and by themselves they have limited utility for discriminating between 
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health and defecatory disorders. Hence, FDDs are best identified by a combination of 
dyssynergic patterns during attempted defecation and other findings (see diagnostic criteria).
Epidemiology
The prevalence of FDDs in the general population is unknown because the diagnosis 
requires laboratory testing. At tertiary referral centers, the prevalence of dyssynergic 
defecation among patients with chronic constipation has ranged widely, from 20% to 
81%.151–155 However, the prevalence of dyssynergia may have been overestimated due to 
the high false-positive rates seen in some studies.156,157 In one tertiary care center, the 
prevalence of dyssynergia was 3 times higher in women than men, but was similar in 
younger and older individuals.140
F3. Diagnostic Criteriaa for Functional Defecation Disorders
1. The patient must satisfy diagnostic criteria for functional constipation 
and/or irritable bowel syndrome with constipation
2. During repeated attempts to defecate, there must be features of 
impaired evacuation, as demonstrated by 2 of the following 3 tests:
a. Abnormal balloon expulsion test
b. Abnormal anorectal evacuation pattern with manometry 
or anal surface EMG
c. Impaired rectal evacuation by imaging
Subcategories F3a and F3b apply to patients who satisfy criteria for FDD
F3a. Diagnostic Criteria for Inadequate Defecatory Propulsion
Inadequate propulsive forces as measured with manometry with or without inappropriate 
contraction of the anal sphincter and/or pelvic floor musclesb
F3b. Diagnostic Criteria for Dyssynergic Defecation
Inappropriate contraction of the pelvic floor as measured with anal surface EMG or 
manometry with adequate propulsive forces during attempted defecation b
aCriteria fulfilled for the last 3 months with symptom onset at least 6 months before 
diagnosis.
bThese criteria are defined by age- and sex-appropriate normal values for the technique.
Justification for Changes in Diagnostic Criteria
In the previous classification, only patients with functional constipation, but not 
constipation-predominant IBS, were eligible to be diagnosed with a defecatory disorder. 
Since then, an association between IBS and pelvic floor dysfunction has been 
recognized,158,159 and patients with dyssynergic defecation can be effectively treated with 
biofeedback therapy irrespective of coexistent IBS.160 Hence, the Rome IV criteria have 
been revised to include patients with constipation-predominant or mixed IBS. The criteria 
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for “inadequate propulsive forces” and “inappropriate contraction of the anal sphincter 
and/or pelvic floor muscles” are no longer specified because they vary among different 
techniques.141,142,161
Clinical Evaluation
A detailed assessment of bowel symptoms (eg, prolonged or excessive straining, feeling of 
incomplete evacuation after defecation, digital facilitation of defecation) and a meticulous 
DRE often raise suspicion for an FDD. Bowel diaries avoid the limitation of recall bias 
inherent to questionnaires and an interview. In a single study, the DRE has a sensitivity of 
75% and specificity of 87% for detecting dyssynergia,162 which is associated with 
contraction or failure to relax the puborectalis and/or anal sphincter muscle and reduced 
perineal descent when patients try to expel the examining finger.
Physiologic studies should be considered if there is insufficient response to conservative 
treatment, for example, education regarding normal bowel habits, increased dietary fiber and 
liquids, and elimination of medications with constipating side effects whenever possible. 
These studies should include balloon expulsion test, anorectal manometry, and if necessary, 
defecography-imaging to aid in diagnosis of FDD. There is no single “gold standard” 
diagnostic test to diagnose FDD and limited agreement among various tests.
Balloon expulsion test—Rectal expulsion can be evaluated by asking patients to expel 
balloons filled with water or air from the rectum. 143,146,163 The time required to expel the 
balloon depends on the method used and ranges from 1 minute to expel a 50-mL balloon 
filled with water 145,164,165 to 2 minutes.148 It is recommended that the patient sit on a 
commode chair behind a privacy screen.148 The balloon expulsion test is a useful screening 
test for FDD, but it does not define the mechanism of disordered defecation. Because the 
balloon may not mimic the patients’ stool, a normal balloon expulsion study does not always 
exclude a defecation disorder.141
Manometric assessment—Traditionally, ARM has been considered essential for 
diagnosis of FDDs. This assessment includes measurement of intrarectal pressures during 
attempted defecation, and measurement of anal pressures and/or EMG activity during 
attempted defecation. However, given the overlap of findings in asymptomatic people and 
patients with FDD, the precise criteria and utility of manometry for diagnosing defecatory 
disorders is in evolution. Also, body position and manometry systems may influence 
findings.
A normal pattern is characterized by increased intrarectal pressure associated with anal 
relaxation. A study of 100 patients with a 6-sensor, solid-state manometry system identified 
4 patterns of FDD.141 Two patterns, types I and III, describe dyssynergic defecation. Type I 
pattern is characterized by increased intrarectal pressure (≥45 mm Hg) and increased anal 
pressure reflecting contraction of the anal sphincter. Type III pattern is characterized by 
increased intrarectal pressure (≥45 mm Hg) with absent or insufficient (<20%) relaxation of 
the anal sphincter. Inadequate propulsion (intrarectal pressure <45 mm Hg) may be 
associated with paradoxical contraction (type II pattern) or insufficient relaxation (<20%) of 
anal sphincter (type IV pattern). During testing 1 month later, the abnormal patterns were 
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reproducible in 51 of 53 patients.141 Levels of inter-observer agreement for identifying these 
patterns was substantial for types I and IV dyssynergia, moderate for normal defecation 
pattern, and fair for types II and III dyssynergia.161 A study using high-resolution 
manometry in 62 healthy women and 295 women with chronic constipation identified 3 
phenotypes (high anal, low rectal, and hybrid) that discriminated among patients with 
normal and abnormal balloon expulsion time with 75% sensitivity and 75% specificity.165
Defecography—Defecography is a radiologic technique used to evaluate the rectum and 
pelvic floor during attempted defecation.3,166 This test can detect structural abnormalities 
(rectocele, enterocele, intussusception, rectal prolapse, and megarectum) and assess 
functional parameters (anorectal angle at rest and during straining, perineal descent, anal 
diameter, indentation of the puborectalis, degree of rectal emptying).
The diagnostic value of defecography is unclear,7 but is still employed when ARM and 
balloon expulsion test are equivocal, or for patients who are unable to evacuate a balloon, 
but who relax the pelvic floor normally during simulated defecation. In several European 
countries, defecography is the primary modality for identifying FDD.
Magnetic resonance defecography images anorectal motion and rectal evacuation in real 
time. Advantages include better resolution of soft tissue surrounding the rectum, improved 
ability to visualize anal sphincter and levator ani muscles, and lack of radiation. MRI is 
particularly useful in patients with normal balloon expulsion to identify structural lesions 
and disordered defecation, and to guide surgical therapy, for example for rectoceles and 
cystoceles.102,167
Radio-opaque marker test of whole gut transit time—By itself, slow colonic transit 
is not diagnostic of a primary colonic motility disorder because slow transit constipation 
exists independent of, or co-exists with, FDDs and up to two-thirds of patients with a 
defecation disorder also have delayed colonic transit.141,168,169 In one study, colonic transit 
improved after biofeedback therapy for outlet dysfunction, which suggests that outlet 
dysfunction was responsible for delayed colonic transit.168 Colonic transit time can be 
measured by obtaining abdominal radiographs after patients ingest radio-opaque markers,170 
a wireless motility capsule,171–173 or by scintigraphy. The wireless motility capsule and 
scintigraphy can also measure gastric emptying and small intestinal transit, which may also 
be delayed in constipated patients.174
Utility of anorectal testing for functional defecation disorders—The role of 
diagnostic testing was evaluated by assessing anorectal manometry, balloon expulsion test, 
defecography, and colonic transit in 100 consecutive patients with symptoms of difficult 
defecation.141 In this group, anal manometry and balloon expulsion were normal in 30%. 
Among 70 patients with abnormal manometry, balloon expulsion was abnormal in 42 
patients (60%) indicative of FDD. Among 28 patients with abnormal manometry and normal 
balloon expulsion, defecography showed features of dyssynergic defecation in 7 patients 
(25%). Because a considerable proportion of healthy people exhibit dyssynergia when tested 
with high-resolution manometry, the utility of high-resolution manometry for identifying 
DD is unclear.142,161 Based on these results, abnormal findings with 2 of 3 tests (ie, 
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anorectal manometry, balloon expulsion test, and defecography) are required to confirm the 
diagnosis of FDD.
Pathophysiology
FDDs are probably acquired but subliminal behavioral disorders, particularly in patients who 
learn to relax the external anal sphincter and puborectalis muscles appropriately when 
provided with biofeedback training.
Anxiety and/or psychological stress may also contribute to the development of dyssynergic 
defecation by increasing skeletal muscle tension,175 and one study found that patients with 
dyssynergic defecation had higher scores for anxiety, depression, paranoid ideation, hostility, 
and obsessive compulsiveness than those patients with slow transit constipation.176 
Psychological distress seem to have a negative impact on the outcome of biofeedback 
therapy.177 Uncontrolled studies have reported sexual abuse in 22% of women with FDD, 
and 40% of women with functional lower gut disorders, including FDD.140,178
Treatment
Historically, 2 types of pelvic floor training involving behavioral modification have been 
advocated: biofeedback training in which pressure sensors or EMG placed inside the anus 
and rectum provide feedback to the patient on muscle activity179 and simulated defecation in 
which the patient practices evacuating an artificial stool surrogate.179,180 Simulated 
defecation has been combined with diaphragmatic muscle training by some 
investigators.179,181 Recent randomized controlled trials have used multicomponent 
biofeedback treatment,182 which includes the following four steps (Table 3):
1. Patient education: Explain to patients that they inadvertently squeeze or 
fail to relax their anus when they are straining.
2. Enhance push effort: Teach the patients to effectively push, when 
straining, by appropriately increasing the intra-abdominal pressure; use 
feedback from rectal sensor regarding abdominal and diaphragmatic push 
effort to expel stool.
3. Train to relax pelvic floor muscles: Teach patients to relax their pelvic 
floor muscles when straining. This skill can be taught by providing visual 
feedback regarding anal canal pressure or EMG activity (Figure 2).
4. Practice simulated defecation: Educate patient to practice defecation and 
expulsion of a lubricated, inflated balloon while the therapist assists by 
gently pulling on the catheter.
Several randomized controlled trials have demonstrated that biofeedback is safe and 
effective treatment for dyssynergic defecation (Table 3). Biofeedback therapy was more 
effective than sham feedback, pelvic floor exercises, laxatives, and muscle relaxant drugs, 
both on a short- and long-term basis without side effects.116–117,183–185 Biofeedback therapy 
is to be regarded as first-choice treatment for FDD whenever dedicated expertise is available. 
Biofeedback therapy is not effective for constipated patients without FDD.116 Whether 
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biofeedback is as effective for altered defecatory propulsion as it is for dyssynergic 
defecation is not known.
Recommendations for Future Research
1. Multicenter studies of normal physiology of defecation and fecal 
continence using newer diagnostic modalities in large groups of subjects 
stratified for age, sex, and parity.
2. Define the role of rectal contraction and sensation in disordered 
defecation, especially to understand dyssynergic defecation vs inadequate 
propulsion.
3. Evaluate interaction(s) between stool consistency, sphincter weakness, 
sphincter defects, rectal sensation and compliance, and neurogenic 
sphincter injury in FI.
4. Randomized, blinded controlled study of biofeedback treatment for 
dyssynergic defecation, especially to examine its generalizability for FDD.
5. Examine the natural history, duration, and phenotype of anorectal pain 
syndromes and perform randomized studies of drugs, biofeedback, and 
other treatments for levator ani syndrome.
6. Randomized controlled trials of bowel management, biofeedback, sacral 
nerve stimulation, anal bulking agents and sphincteroplasty in FI, 
including mechanistic understanding and well-designed outcome 
measures.
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Figure 1. 
Anatomy of the anal canal and rectum, which displays the key physiologic mechanisms for 
continence and defecation.
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Figure 2. 
Effect of biofeedback therapy on dyssynergia in 1 patient before and after treatment. Panel A 
shows baseline intrarectal and anal sphincter pressures. There is inadequate propulsion and 
paradoxical anal contraction. Panel B shows that after learning diaphragmatic breathing 
technique, the pushing effort has improved but patient still shows paradoxical contraction. 
Panel C shows coordinated relaxation, with an increase in intrarectal pressure and relaxation 
of the anal sphincter. Adapted from Rao, with permission.187
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Table 1
Functional Anorectal Disorders
F. Functional anorectal disorders
  F1. Fecal incontinence
  F2. Functional anorectal pain
    F2a. Levator ani syndrome
    F2b. Unspecifed functional anorectal pain
    F2c. Proctalgia fugax
  F3. Functional defecation disorders
    F3a. Dyssynergic defecation
    F3b. Inadequate defecatory propulsion
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Table 2
Common Causes of Fecal Incontinence
Anal sphincter weakness
  Traumatic: obstetric, surgical (eg, hemorrhoidectomy, internal
sphincterotomy, fistulectomy)
  Nontraumatic: scleroderma, idiopathic internal sphincter
degeneration
  Neuropathy
  Peripheral (eg, pudendal) or generalized (eg, diabetes mellitus)
Pelvic floor disorders
  Rectal prolapse, descending perineum syndrome
Disorders affecting rectal capacity and/or sensationa
  Inflammatory conditions: radiation proctitis, Crohn’s disease,
ulcerative colitis
    Anorectal surgery (pouch, anterior resection)
    Rectal hyposensitivity
    Rectal hypersensitivity
Central nervous system disorders
  Dementia, stroke, brain tumors, multiple sclerosis, spinal cord
lesions
Psychiatric diseases, behavioral disorders
Bowel disturbances
  Irritable bowel syndrome, post-cholecystectomy diarrhea
  Constipation and fecal retention with overflow
a
These conditions may also be associated with diarrhea.
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